Well we know for fact that just a few weeks ago they were still waiting on IRB approval for the TNBC and P2B trials, that part was out of their hands. The H&N trial they may have been holding off until after the R/S, which explains the clinicaltrialsgov site listing them as recruiting as of the 19th (tues). I don't know the process of enrolling patients, it could be that no one was waiting to get into the trial, it could be that there is a testing process that has to take place before actual treatment starts. Hopefully we see 1st person treated Mon/Tue next week.
dirk, you are correct there is no Abstract that we are aware of. It is possible that MCC data was submitted as late breaking. Knowing that the last patient was enrolled in Jan, there is a possibility that the final patient has completed treatment within the allowable window. Though I would not hold my breath on that theory.
wait, obviously the endpoints of the study are unknown to us, so your assumption is just as good as mine. The Adaptive T-Cell combination trial had an endpoint of 50week survival data (based on what I read). I don't know for sure that is the same endpoint for IL-12, I am not familiar enough with PLX3397 to say what the appropriate endpoint should be. It may be another year before we see any data.
wait, the plexxikon mouse trial combined with adaptive t-cells was a 50 week trial, I would expect it to be the same length for us.
there are several pre clinical mouse trials that have not been fully released. In Oct 13 they released interim combination data using PD1, PDL1, and CTLA4 in mice, that was a 100% response in all mice, but the full data of complete response etc was never released. I'm sure they have some systemic trials that have not been fully released either.
well we know Dr. Pierce did present some unpublished data at PEGS, and technically this release does not say "unpublished", though it does read that way. Unfortunately for many of us who invested a year to early in this company we were in at the time that Punit was focused on building a company, now it is apparent he is focusing on credibility and stock price as much as the company operations. Don't be surprised if there are not more events in the coming few weeks that we are not expecting.
jham, I'd wager that it is additional data on TIL generation from MCC and Melanoma trials currently being conducted. I still believe that MCC final data gets presented at ASCO as a late breaking abstract. We shall see. Glad to see some news coming out, we should climb rapidly now and get back to a fairer valuation around $10
Sal wasn't man enough to own his mistakes, I guarantee he isn't man enough to short this to the tune of 50k shares. Just wait, you will see
Sal, I never criticized you for going somewhere else with your money. You have fixated on me, and blamed Punit for your flawed investment. So be a real man, and short your 50k shares, or apologize. I doubt you will do either, but feel free to talk all you want. You are a buffoon and the coming weeks will prove it.
News to be expected in the next 3 weeks... MCC final data presented at ASCO as a late breaking abstract (just a guess), TNBC trial start, H&N trial start, P2B trial start, insider buying.
Hurry up and short the other 47k shares would you. Let us know what price
keep us up to date sal. Make sure you use lots of derogatory language when addressing us.
Yes. I guess the Scottrade system automatically charged $20 for a new Cusip number. My broker said he was going to fix it. Was a bit upset I got the same fee on an account that only had a couple thousand shares as the ones that had larger holdings.
If he wanted to short, he could easily short 1000 at a time right now. he won't do it.